Latest Rosiglitazone Stories
PHILADELPHIA, Oct. 30 /PRNewswire-FirstCall/ -- GlaxoSmithKline today issued the following response to a petition filed by Public Citizen to the U.S.
Treatment for diabetic Americans has doubled in cost during the past six years. Last year, the bill hit an eye-popping $12.5 billion.
WALTHAM, Mass., Sept.
Novo Nordisk has presented data from a Phase III clinical study that demonstrated adding the investigational new drug liraglutide, a human GLP-1 analog, to metformin and rosiglitazone in the treatment of type 2 diabetes, leads to improved blood glucose lowering, weight loss, blood pressure reduction and improvements in beta-cell functioning.
New data analyses presented at the 44th Annual Meeting of the European Association for the Study of Diabetes (EASD) showed initial combination therapy with the dipeptidyl peptidase-4 (DPP-4) inhibitor, JANUVIA(TM) (sitagliptin), and metformin provided improvements in blood sugar levels (as measured by A1C(1)) over two years of treatment and was generally well tolerated.
Results from two 24-week Phase III studies presented at the 44th European Association for the Study of Diabetes Annual Meeting demonstrated that ONGLYZA(TM) (saxagliptin), an investigational selective inhibitor with extended binding to the dipeptidyl peptidase-4 (DPP-4) enzyme in development by Bristol-Myers Squibb Company (NYSE: BMY) and AstraZeneca (NYSE: AZN), produced significant reductions across all key measures of glucose control studied (glycosylated hemoglobin level (A1C), fasting...
A class of oral drugs used to treat type 2 diabetes may increase the risk of heart failure, two Wake Forest University School of Medicine faculty members said. Dr. Sonal Singh and Dr. Curt D.
A wrongful death suit was filed against GlaxoSmithKline, SmithKline Beecham, and McKesson Corporation in California Superior Court, charging that Avandia, prescribed for Type 2 Diabetes, led to heart attacks, congestive heart failure and other fatal cardiovascular injuries in seven individuals.
PHILADELPHIA, July 14 /PRNewswire-FirstCall/ -- GlaxoSmithKline announces today that the U.S.
- totally perplexed and mixed up.